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Aim of the study: Thromboprophy-
laxis in cancer patients during hospi-
talization reduces the risk of venous 
thromboembolism (VTE). 
Material and methods: To assess the 
underuse and the overuse of throm-
boprophylaxis in cancer patients at 
a  tertiary oncology department, we 
retrospectively analyzed 1983 consec-
utive hospitalizations of 498 cancer 
patients who received chemotherapy 
from October 2016 to May 2017. The 
Padua prediction score (≥ 4 points) 
and Caprini risk assessment (≥ 5 
points) were used to identify patients 
at high risk of VTE. 
Results: The majority of individuals (n 
= 363, 72.9%) suffered from advanced 
lung cancer. We found that 419 
(84.14%) patients received thrombo-
prophylaxis with enoxaparin 40 mg qd, 
including 181 (43.2%) individuals us-
ing concomitant mechanical throm-
boprophylaxis. As few as 44 (8.8%) 
and 11 (2.2%) patients did not re-
ceive thromboprophylaxis despite 
high VTE risk based on the Caprini 
risk assessment and Padua prediction 
score, respectively (p < 0.001). The 
number of patients without high risk 
of VTE, who received pharmacologi-
cal thromboprophylaxis, was higher 
when the Padua prediction score was 
used compared with the Caprini risk 
assessment (n = 391 [78.5%] vs. n = 
210 [42.2%], respectively; p < 0.001). 
Three patients (0.6%) experienced 
vascular events during hospital stay, 
including one symptomatic deep-
vein thrombosis. No major bleeding 
was observed. Predictors of throm-
boprophylaxis overuse were as fol-
lows: previous VTE and abnormal 
pulmonary function for both scales. 
Conclusions: This study shows that 
thromboprophylaxis in cancer in pa-
tients undergoing chemotherapy is 
suboptimal in Poland in part due to 
the use of various VTE risk scores 
yielding discrepant results in everyday 
practice.
Key words: thromboprophylaxis, can-
cer, hospitalisation, chemotherapy, 
the overuse of thromboprophylaxis.
Contemp Oncol (Pozn) 2018; 22 (1): 31–36
DOI: https://doi.org/10.5114/wo.2018.74391
Original paper
The comparison between Caprini 
and Padua VTE risk assessment 
models for hospitalised cancer 
patients undergoing chemotherapy 
at the tertiary oncology department 
in Poland: is pharmacological 
thromboprophylaxis overused?
Robert F. Łukaszuk1, Justyna Dolna-Michno1, Krzysztof Plens2,  
Grzegorz Czyżewicz3, Anetta Undas4,5
1Department of Pulmonology, John Paul II Hospital, Krakow, Poland 
2KCRI, Krakow, Poland 
3Department of Oncology, John Paul II Hospital, Krakow, Poland 
4Center for Research and Medical Technology, John Paul II Hospital, Krakow, Poland  
5Institute of Cardiology Jagiellonian University Medical College, Krakow, Poland
Introduction
Hospital stay precedes 10–20% of venous thromboembolism (VTE) epi-
sodes [1–3] and 10% of inhospital deaths are related to VTE [4, 5]. Cancer 
is associated with a 4.1-fold greater risk of thrombosis [6, 7]. Approximately 
20% of cancer patients develop VTE, which represents a frequent cause of 
death in these patients [8]. The key VTE risk factors are the primary site of 
cancer and the presence of distant metastasis [6, 8–12]. Patients with can-
cer and co-existing VTE have a 2-fold or greater mortality compared with 
those without thrombosis, even after adjusting for the disease stage [12, 
13]. Lung cancer is the most common malignancy in malignancy-associated 
VTE patients [14]. Blom et al. [15] demonstrated that this risk among lung 
cancer patients increased 20-fold compared with the general population 
and patients diagnosed with lung adenocarcinoma have a higher risk of VTE 
than those suffering from squamous cell carcinoma. Over 3% of lung cancer 
patients develop VTE within 2 years since diagnosis [16] and such episodes 
are associated with a 50% higher risk of death within 2 years [17]. 
The aim of our study is to evaluate the risk of VTE among cancer inpa-
tients and the use of thromboprophylaxis in order to assess the current 
trends in thromboprophylaxis among Polish inpatients.
Material and methods
We enrolled all consecutive patients aged 18 years or more with the con-
firmed diagnosis of cancer who were hospitalized from October 2016 to May 
2017 in the Department of Oncology, John Paul II Hospital in Krakow, Poland. 
Solely patients who stayed in hospital for more than 24 hours were eligible. 
No exclusion criteria were used.
Demographic and clinical data were collected using questionnaires. The 
cancer stage was established based on clinical assessment and imaging 
based on the 8th Edition of the UICC TNM classification of Malignant Tu-
mours [18] . Patients admitted to hospital more than once due to a cycle of 
chemotherapy were scored during the last stay within the given period of 
time. The study was conducted in accordance with local legal regulations.
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We used two validated scoring systems to identify pa-
tients at high risk for VTE when hospitalized, i.e. the Pad-
ua prediction score and Caprini VTE risk assessment [3, 19, 
20]. The Padua prediction score, indicating a high risk, was 
defined as a score of 4 or higher. The Caprini VTE risk as-
sessment identifies high risk as a score of 5 or higher. Phar-
macological prophylaxis was administration of enoxaparin 
(40 mg once daily s.c. throughout hospitalisation). Mechani-
cal prophylaxis (graduated compression stockings) was also 
recorded. The decision regarding thromboprophylaxis was 
at the managing physician’s discretion. Not using thrombo-
prophylaxis in patients at high risk for VTE identified using 
one of the scoring systems was recognized as the underuse 
of prophylaxis while the overuse was recognized as using 
any thromboprophylaxis in patients identified as at low risk.
Statistical analysis
Variables were presented as numbers and percentag-
es for categorical variables or by median and interquartile 
range for continuous parameters. Nominal variables in the 
subgroups were compared with the Pearson’s χ2 test or 
the Fisher’s exact test for 2 × 2 tables as appropriate. Con-
tinuous variables were compared using the Mann-Whitney 
U test. The comparison of two scoring systems was per-
formed using the McNemara’s test. To identify indepen-
dent predictors of thromboprophylaxis overuse, univariate 
logistic regression analysis was performed. Associations 
between two variables were expressed as odds ratios (OR) 
along with 95% confidence intervals (95% CI). All p-values 
were two-sided and considered statistically significant if 
below 0.05. All calculations were done with JMP®, Version 
13.1.0 SAS Institute Inc., Cary, NC.
Results
We enrolled 1983 consecutive hospitalisations of 498 
individuals, including 318 (63.8%) men (Table 1). Median 
age was 64.85 (range from 18 to 86) years. Median dura-
tion of hospitalisation was 3 (range from 2 to 5) days. The 
majority of individuals (n = 363 [72.9%]) suffered from 
lung cancer (Table 1). We identified 419 (84.14%) patients 
who received thromboprophylaxis with enoxaparin includ-
ing 181 (43.2%) patients using concomitant mechanical 
thromboprophylaxis. There were no patients receiving the 
latter intervention among subjects without pharmacologi-
cal thromboprophylaxis. One patient (0.2%) suffered from 
cancer-related VTE diagnosed shortly before the hospital. 
None of the patients received oral anticoagulants. Partic-
ipants received enoxyparixe according to scoring system 
results despite anti-platelet agents which they could use 
due to coronary artery disease. None of the individuals 
received anti-platelet agents as a type of thromboprophy-
laxis. The characteristic of study population was placed in 
Table 1. Types of chemotherapy in association with throm-
boprophylaxis are listed in Table 2. Chemotherapy was 
stopped in 12 (2.4%) patients due to side effects.
The Padua prediction score
As shown in Table 3, using the Padua prediction score, 
we identified 39 (7.8%) patients at high risk of VTE, includ-
ing 28 (71.8%) who received thromboprophylaxis. Eleven 
(28.2%) high-risk patients did not receive thromboprophy-
laxis. There were no prophylaxis related intergroup differ-
ences depending on the type of cancer or its stage. Overall, 
the majority of inpatients did not have high VTE risk as-
sessed using the Padua prediction score and 71.8% of high 
risk patients received thromboprophylaxis with the con-
comitant large overuse of pharmacological prophylaxis.
Caprini VTE risk assessment
We identified 257 (51.6%) patients at high risk for VTE 
(Table 4), including 213 (82.9%) who received thrombopro-
phylaxis, and only 44 (17.1%) who did not. The number of in-
dividuals at low risk for VTE was 241 (48.4%), including 210 
(87.1%) receiving thromboprophylaxis despite the low risk. 
The comparison of two systems
As shown in Table 5, the Caprini risk assessment clas-
sified more cancer inpatients into the high VTE risk group. 
The differences between two systems in terms of propor-
tions of subjects at high and low VTE risk were highly sig-
nificant. 
Predictors of the overuse of thromboprophylaxis
Predictors of overused thromboprophylaxis were previ-
ous VTE and abnormal pulmonary function for both scales, 
while age over 75 years and swollen legs were identified for 
the Caprini risk assessment alone and varicose veins for 
Padua prediction score alone (Table 1). The type of chemo-
therapy did not affect the overuse of thromboprophylaxis.
Clinical events during hospitalisation
Three vascular thromboembolic events were recorded 
in 3 patients (0.60%) during hospital stay. There were non-
ST elevation myocardial infarction, ST elevation myocar-
dial infarction and right-sided deep vein thrombosis. No 
major bleeding was observed. Hemoptysis probably asso-
ciated with lung cancer was observed in 8 (1.6%) patients 
who reported this symptom prior to admission and re-
ceived thromboprophylaxis on the ward without increased 
bleeding. No in-hospital deaths were observed.
Discussion
This study shows that nowadays thromboprophylaxis is 
suboptimal in lung cancer patients hospitalized for che-
motherapy. Although patients eligible for thromboprophy-
laxis represented a small proportion of our study group 
when assessing the VTE risk using 2 scoring systems, 
most received the recommended subcutaneous LMWH. 
The overuse of pharmacological thromboprophylaxis was 
observed in our patients regardless of the scoring system 
used, although no major bleeding during hospital stay was 
observed. Given large differences in the proportions of 
cancer patients categorized into the high VTE risk groups 
between the 2 scoring systems, it might be speculated 
that advanced cancer inpatients undergoing chemothera-
py should be evaluated using other systems than the two 
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Table 1. The study population and thromboprophylaxis overuse predictors
All patients 
(n = 498)
Patients who 
received 
thrombo-
prophylaxis 
(n = 419)
Patients who 
did not receive 
thrombo-
prophylaxis
(n = 79)
p-value Caprini risk assessment, 
overuse predictors
Padua prediction score, 
overuse predictors
OR (95% CI) p-value OR (95% CI) p-value
Age, years 64.9 (59.5–70) 64.9 (58.9–70.0) 64.7 (60.0–69.3) 0.76 0.890 (0.866–0.915) < 0.001 0.982 (0.959–1.006) 0.15
Men, n (%) 318 (63.8) 274 (65.3) 44 (55.7) 0.09 1.180 (0.807–1.726) 0.40 1.596 (1.033–2.466 0.035
Overweight, n (%) 223 (44.8) 199 (47.5) 24 (30.3) 0.005 0.157 (0.104–0.237) < 0.001 1.550 (0.997–2.409) 0.051
Comorbidities, n (%)
COPD or asthma 93 (18.7) 75 (17.9) 18 (22.8) 0.31 0.696 (0.435–1.115) 0.13 0.691 (0.411–1.160) 0.16
Diabetes mellitus 66 (13.3) 54 (12.9) 12 (15.2) 0.58 0.923 (0.528–1.614) 0.78 3.199 (1.245–8.216) 0.016
Chronic kidney 
disease
8 (1.6) 8 (1.9) 0 (0.0) 0.37 0.400 (0.274–0.584) < 0.001 0.552 (0.359–0.849) 0.007
Arterial 
hypertension or 
coronary artery 
disease
208 (41.8) 167 (39.9) 41 (51.9) 0.05 0.378 (0.104–1.370) 0.14 0.834 (0.454–1.533) 0.56
Previous surgery 58 (11.6) 55 (13.1) 3 (3.8) 0.02 1.342 (0.739–2.438) 0.33 1.044 (0.502–2.171) 0.91
Varicose veins 24 (4.8) 11 (2.6) 13 (16.5) < 0.001 – – 0.060 (0.022–0.165) < 0.001
Thromboembolism, n (%)
Previous VTE 6 (1.2) 3 (0.7) 3 (3.8) 0.05 0.280 (0.032–2.415) 0.25 0.268 (0.053–1.348) 0.11
Previous VKA 
treatment
31 (6.2) 23 (5.5) 8 (10.1) 0.13 0.139 (0.042–0.465) 0.001 0.349 (0.165–0.738) 0.006
Mechanical 
thromboprophylaxis
181 (36.3) 181 (43.2) 0 (0.0) < 0.001 – – – –
The histopathologic type of cancer, n (%)
Squamous-cell 
cancer
107 (21.5) 93 (22.2) 14 (17.7) 0.37 1.764 (1.147–2.714) 0.01 1.345 (0.776–2.331) 0.29
Lung 
adenocarcinoma
193 (38.8) 167 (39.9) 26 (32.9) 0.24 0.844 (0.584–1.219) 0.37 1.256 (0.803–1.963) 0.32
Small-cell lung 
cancer
125 (25.1) 98 (23.4) 27 (34.2) 0.04 0.615 (0.402–0.942) 0.03 0.549 (0.346–0.874) 0.011
Mesothelioma 2 (0.4) 2 (0.5) 0 (0.0) 1.00 – – – –
NOS 47 (9.4) 39 (9.3) 8 (10.1) 0.82 1.277 (0.699–2.334) 0.43 1.014 (0.487–2.112) 0.97
Other cancers 24 (4.8) 20 (4.7) 4 (5.1) 1.00 1.013 (0.441–2.328) 0.98 1.388 (0.464–4.151) 0.56
The stage of cancer, n (%)
I 1 (0.2) 1 (0.2) 0 (0.0) 1.00 – – – –
II 14 (2.8) 11 (2.6) 3 (3.8) 0.47 0.378 (0.104–1.370) 0.14 0.676 (0.208–2.199) 0.51
III 161 (32.3) 145 (34.6) 16 (20.2) 0.01 1.180 (0.807–1.726) 0.39 1.865 (1.132–3.074) 0.014
IV 322 (64.6) 262 (62.5) 60 (75.9) 0.02 0.924 (0.636–1.340) 0.68 0.582 (0.361–0.938) 0.026
VTE risk scores, n (%)
Padua prediction 
score: low risk 
(< 4 points)
459 (92.2) 391 (78.5) 68 (21.5) 0.03 – – – –
Padua prediction 
score: high risk  
(≥ 4 points)
39 (7.8) 28 (13.9) 11 (2.2) 0.03 – – – –
Caprini VTE risk 
assessment score: 
low risk (< 5 points)
241 (48.4) 206 (41.4) 35 (7.1) 0.43 – – – –
Caprini VTE risk 
assessment score: 
high risk (≥ 5 points)
257 (51.6) 213 (42.8) 44 (8.8) 0.43 – – – –
Data are presented as median and interquartile range or number (percentage)
COPD – chronic obstructive pulmonary disease; VTE – venous thromboembolism; VKA – vitamin K antagonist; NOS – non-small-cell carcinoma, not otherwise 
specified; OR – odds ratio; CI – confidence interval.
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most commonly used in medical non-cancer hospitalized 
patients.
Our study reported that prophylactic LMWH is more 
commonly used among lung cancer inpatients compared 
with those suffering from a wide range of pulmonary dis-
eases in the same Polish tertiary hospital [20]. Awareness 
of the VTE risk, as the most common preventable cause of 
death in hospitals, has increased in Poland, where several 
local guidelines have been issued over the last 10 years [10, 
17]. Polish guidelines on the prevention of VTE in patients 
with cancer conservatively treated have recommended us-
ing the Padua Prediction Score to estimate the risk of VTE 
[17]. However, the current study showed that this system 
identifies high VTE risk in a small subset of hospitalized 
patients undergoing chemotherapy and the proportion is 
much lower compared with another system introduced 
by Caprini. It indicates that a real clinical value of the cur-
rent assessment models for cancer inpatients should be 
re-evaluated and there is a need for modifications of the 
scoring systems to improve VTE risk assessment in cancer 
inpatients.
To our knowledge, the two scoring systems used in this 
study have not been tested in cancer inpatients yet. Our 
study suggests that in cancer patients the Caprini risk as-
sessment might be preferred. Larger prospective studies 
are needed to validate this observation, which appears in 
line with other studies in different inpatient groups. Liu X 
et al. showed in Chinese inpatients that Caprini risk as-
sessment had a higher sensitivity and both positive and 
negative predictive values than the Padua prediction score 
in hospitalized patients [21]. Zhou HX et al. reported similar 
findings and also noticed that the Caprini risk assessment 
score could be helpful in predicting the risk of recurrent 
VTE in inpatients [22].
A surprising overuse of thromboprophylaxis with LMWH 
in cancer inpatients observed in the current study deserves 
a comment. It might be speculated that the overuse of 
prophylactic LMWH was associated with physician’s con-
Table 2. Agents used during chemotherapy in the study patients 
Medication, n (%) The whole 
population
(n = 498)
Patients who received 
thromboprophy-laxis 
(n = 419)
Patients who did not 
receive thromboprophylaxis 
(n = 79)
p-value
EGFR inhibitor 45 (9.0) 42 (10.0) 3 (3.8) 0.08
Chemotherapy based on 5-fluorouracil 20 (4.0) 19 (4.5) 1 (1.3) 0.22
Platine-based chemotherapy agents 347 (69.7) 288 (68.7) 67 (84.8) 0.01
Other chemotherapeutics 79 (15.9) 64 (15.3) 14 (17.7) 0.58
Dexamethasone 453 (91.0) 377 (90.0) 76 (96.2) 0.08
Data are presented number (percentage)
EGFR – epidermal growth factor receptor
Table 3. Use of thromboprophylaxis according to Padua prediction score 
Patients who should 
receive thrombopro-
phylaxis 
Patients who 
should not receive 
thromboprophylaxis 
Patients who 
received thrombo- 
prophylaxis 
Patients who did not 
receive thrombopro-
phylaxis despite indication
Patients received 
thromboprophylaxis 
without indication
p-value
Padua 
prediction score 
≥ 4 points, n (%)
39 (7.8) 459 (92.2) 28 (5.6) 11 (2.2) 391 (78.5) < 0.001
The histopathological type of cancer, n (%)
Squamous-cell 
cancer
7 (17.9) 100 (21.8) 93 (22.2) 2 (18.2) 88 (22.5) 0.80
Lung 
adenocarcinoma 
15 (38.5) 178 (38.8) 167 (39.9) 4 (36,4) 156 (39.9) 0.97
Small-cell lung 
cancer
15 (38.5) 110 (23.9) 98 (23.4) 5 (45.4) 88 (22.5) 0.06
Mesothelioma 0 (0.0) 2 (0.4) 2 (0.5) 0 (0.0) 2 (0.5) 0.90
NOS 2 (5.1) 45 (9.8) 39 (9.3) 0 (0.0) 37 (9.5) 0.06
Other cancers 0 (0.0) 24 (5.2) 20 (4.8) 0 (0.0) 20 (5.1) 0.35
The stage of cancer, n (%)
I 0 (0.0) 1 (0.2) 1 (0.2) 0 (0.0) 1 (0,2) 0.95
II 1 (2.6) 13 (2.8) 11 (2.6) 0 (0.0) 10 (2.5) 0.81
III 12 (30.8) 149 (32.5) 145 (34.6) 4 (36.4) 137 (35.1) 0.78
IV 26 (66.7) 296 (64.5) 262 (62.5) 7 (63.6) 243 (62.1) 0.83
Data are presented number (percentage) 
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cerns for a significant risk of VTE among cancer patients, 
which have been observed also by us. Van Es et al. showed 
that 6.1% of patients with solid cancer developed VTE and 
the prediction scores performed poorly in predicting VTE 
in cancer patients [23]. We noticed that most of the over-
use predictors for both scales were well-established risk 
factors of developing VTE [1]. Given high cost of pharma-
cological thromboprophylaxis for our healthcare system 
when overused, administration of LMWH in hospitalized 
cancer patients should be reconsidered and used when in-
dicated. Nevertheless, bleeding complications in patients 
with advanced lung cancer who simultaneously received 
chemotherapy and thromboprophylaxis have been ob-
served infrequently in the published reports, i.e. in 1–3.7% 
of patients [24]. Our analysis showed that knowledge of 
benefits from thromboprophylaxis used in cancer patients 
among oncologists is larger than 10 years ago, when the 
ENDORSE study had been performed and showed no pro-
phylaxis in 67.5% of medical patients, including cancer 
patients [2]. 
Thromboprophylaxis with enoxaparin in cancer inpa-
tients was found to be efficacious, with 3 individuals who 
developed 3 vascular events, including one venous and 
2 arterial episodes. This confirms that thromboprophylaxis 
with LMWH is not effective in preventing myocardial infarc-
tion in subjects with large atherosclerotic burden. Moreover, 
cancer may increase the risk of MI and ischemic stroke [25]. 
Such prothrombotic potential related to cancer cannot be 
abolished using prophylactic doses of enoxaparin which is 
effective in preventing VTE, with a single case of its failure, 
namely venous thrombosis despite prophylaxis.
This study has several limitations. It is retrospective, 
which implies inherent problems with data acquisition 
and its completeness. Patients were not screened for as-
ymptomatic VTE events, therefore the number of episodes 
could be underrepresented in this study. Long-term fol-
low-up in terms of occurrence of VTE after discharge was 
beyond scope of the study. Given growing use of non-vita-
min K antagonist oral anticoagulants worldwide, their role 
in VTE prevention in cancer remains to be established [26]. 
Table 4. Use of thromboprophylaxis according to Caprini VTE risk assessment
Patients who 
should receive 
thrombopro-
phylaxis 
Patients who 
should not receive 
thrombopro-
phylaxis 
Patients who 
received 
thrombopro-
phylaxis
Patients who did not 
receive thrombopro-
phylaxis despite 
indication
Patients who 
received thrombo-
prophylaxis 
without indication
p-value
Caprini VTE risk 
assessment ≥ 5 points, 
n (%)
257 (51.6) 241 (48.4) 213 (42.8) 44 (8.8) 210 (42.2) < 0.001
The histopathologic type of cancer, n (%)
Squamous-cell cancer 44 (17.1) 63 (26.1) 93 (22.2) 7 (15.9) 56 (26.7) 0.03
Lung adenocarcinoma 103 (40.1) 90 (37.3) 167 (39.8) 11 (25,0) 75 (35.7) 0.05
Small-cell lung cancer 76 (29.6) 49 (20.3) 98 (23.4) 19 (43.2) 41 (19.5) 0.01
Mesothelioma 0 (0.0) 2 (0.8) 2 (0.5) 0 (0.0) 2 (0.9) 0.28
NOS 24 (9.3) 23 (9.5) 39 (9.3) 7 (15.9) 22 (10.5) 0.25
Other cancers 10 (3.9) 14 (5.8) 20 (4.8) 0 (0.0) 14 (6.7) 0.33
The stage of cancer, n (%)
I 0 (0.0) 1 (0.4) 1 (0.2) 0 (0.0) 1 (0.5) 0.53
II 9 (3.5) 5 (2.1) 11 (2.6) 1 (2.3) 3 ((1.4) 0.33
III 86 (33.5) 75 (31.1) 145 (34.6) 12 (27.3) 71 (33.8) 0.62
IV 162 (63.1) 160 (66.4) 262 (62.5) 31 (70.4) 131 (62.4) 0.53
Data are presented number (percentage) 
Table 5. Comparison of two scoring systems in the study population 
Caprini VTE risk assessment Padua prediction score p-value
Patients who should receive thromboprophylaxis 257 (51.6) 39 (7.8) < 0.001
Patients who should not receive thromboprophylaxis 241 (48.4) 459 (92.2) < 0.001
Patients who received thromboprophylaxis 213 (42.8) 28 (5.6) < 0.001
Patients who did not receive thromboprophylaxis despite indication 44 (8.8) 11 (2.2) < 0.001
Patients who received thromboprophylaxis without indication 210 (42.2) 391 (78.5) < 0.001
Data are presented as number (percentage) 
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Regarding the data presentation, R2 measures for logistic 
regression models (i.e. Cox and Snell R2) were not reported 
based on lower priority for such measures as compared 
to OR and 95% CI [27]. We cannot exclude using vitamin 
supplements which might affect thrombosis risk, however 
it is unlikely that this factor impacted our results.
In conclusion, the use of thromboprophylaxis in ad-
vanced cancer patients hospitalized due to chemotherapy 
is suboptimal. We showed the overuse of thromboprophy-
laxis in the oncology department however without signif-
icant bleeding risk. Our study suggests that both scoring 
systems are not consistent in the risk evaluation among 
hospitalized cancer patients and there is a need for better 
scoring systems to be applied in this disease.
The authors declare no conflict of interest.
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